Devyser Diagnostics Logo

Devyser Diagnostics

Develops & sells genetic DNA test kits for labs in oncology, transplant & reproductive health.

DVYSR | ST

Overview

Corporate Details

ISIN(s):
SE0016588867 (+1 more)
LEI:
549300RV4Z2K3360CK30
Country:
Sweden
Address:
Instrumentvägen 19, 126 53 Hägersten
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Devyser Diagnostics is a company specializing in the development, manufacture, and sale of advanced diagnostic kits for genetic DNA testing. Serving clinical laboratories, its product portfolio addresses critical areas such as reproductive health, oncology for guiding targeted cancer therapies, and post-transplant monitoring. Devyser's core mission is to simplify and streamline complex laboratory workflows by providing fast, accurate, and user-friendly solutions. The company's end-to-end tests are designed to significantly reduce sample-to-result times and manual handling, aiming to enhance laboratory efficiency, enable quicker patient diagnoses, and advance the accessibility of personalized medicine.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Devyser Diagnostics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Devyser Diagnostics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Devyser Diagnostics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-14 Mia Arnhult Other Buy 7,000 745,290.00 SEK

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea 303360

Talk to a Data Expert

Have a question? We'll get back to you promptly.